227 related articles for article (PubMed ID: 9342579)
1. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Czendlik CH; Sioufi A; Preiswerk G; Howald H
Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.
Müller P; Cohen T; de Gasparo M; Sioufi A; Racine-Poon A; Howald H
Eur J Clin Pharmacol; 1994; 47(3):231-45. PubMed ID: 7867676
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.
Bindschedler M; Degen P; Flesch G; de Gasparo M; Preiswerk G
Eur J Clin Pharmacol; 1997; 52(5):371-8. PubMed ID: 9272406
[TBL] [Abstract][Full Text] [Related]
5. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
Rehman A; Rahman AR; Rasool AH
J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
[TBL] [Abstract][Full Text] [Related]
6. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects.
Morgan JM; Palmisano M; Piraino A; Hirschhorn W; Spencer S; Prasad PP; Ortiz M; Lloyd P
Clin Pharmacol Ther; 1997 Jan; 61(1):35-44. PubMed ID: 9024172
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
8. An interaction study with cimetidine and the new angiotensin II antagonist valsartan.
Schmidt EK; Antonin KH; Flesch G; Racine-Poon A
Eur J Clin Pharmacol; 1998 Feb; 53(6):451-8. PubMed ID: 9551704
[TBL] [Abstract][Full Text] [Related]
9. SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
Hagmann M; Nussberger J; Naudin RB; Burns TS; Karim A; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1997 Apr; 29(4):444-50. PubMed ID: 9156352
[TBL] [Abstract][Full Text] [Related]
10. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
11. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man.
Flesch G; Müller P; Lloyd P
Eur J Clin Pharmacol; 1997; 52(2):115-20. PubMed ID: 9174680
[TBL] [Abstract][Full Text] [Related]
12. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects.
Struck J; Muck P; Trübger D; Handrock R; Weidinger G; Dendorfer A; Dodt C
J Hypertens; 2002 Jun; 20(6):1143-9. PubMed ID: 12023684
[TBL] [Abstract][Full Text] [Related]
13. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
[TBL] [Abstract][Full Text] [Related]
14. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans.
Azizi M; Bissery A; Lamarre-Cliche M; Ménard J
Hypertension; 2004 Apr; 43(4):785-90. PubMed ID: 15023936
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers.
Jung JA; Noh YH; Jin S; Kim MJ; Kim YH; Jung JA; Lim HS; Bae KS
Clin Ther; 2012 Apr; 34(4):958-65. PubMed ID: 22410289
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
Hübner R; Högemann AM; Sunzel M; Riddell JG
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
[TBL] [Abstract][Full Text] [Related]
18. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
[TBL] [Abstract][Full Text] [Related]
19. A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State.
Chen CL; Desai-Krieger D; Ortiz S; Kerolous M; Wright HM; Ghahramani P
Am J Ther; 2015; 22(5):e130-40. PubMed ID: 25853236
[TBL] [Abstract][Full Text] [Related]
20. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]